
    
      In order to improve the treatment outcome for thoracic carcinomas after they become resistant
      to targeted therapy, the investigator is using tumor biopsies at the time of recurrence for
      genomic analysis to identify novel somatic changes in critical genes and gene pathways that
      can potentially be targeted with therapy. The study team is also creating patient-derived
      xenografts to test drug efficacy and optimize personalized therapy for each patient.
    
  